Despite its unique ability to block sodium-glucose linked transporter 2 (SGLT2) in the kidneys and SGLT1 in the intestines, Lexicon’s Zynquista (sotagliflozin) has had difficulty negotiating ...
(RTTNews) - Lexicon Pharmaceuticals Inc. (LXRX) announced that the U.S. Food and Drug Administration's Advisory Committee voted against the company's New Drug Application (NDA) for Zynquista ...
Oct 31 (Reuters) - Independent advisers to the U.S. Food and Drug Administration on Thursday voted against recommending Lexicon Pharmaceuticals' (LXRX.O), opens new tab add-on treatment to insulin ...
Joseph Pantginis has given his Buy rating due to a combination of factors surrounding Lexicon Pharmaceuticals’ sotagliflozin, which is under review by the FDA as an adjunct therapy for Type 1 ...
Providing a diverse range of perspectives from bullish to bearish, 9 analysts have published ratings on Lexicon Pharmaceuticals LXRX in the last three months. The following table summarizes their ...
María Pilar Agustín-Llach [Opens in a new window] and The present study delves into the structure and lexical organization of L1 and L2 mental lexicons. Indirect access to the mental lexicon is ...
Roanna Ruiz has given her Buy rating due to a combination of factors that highlight Lexicon Pharmaceuticals’ strategic advancements and potential for value growth. One significant reason is the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback